Invention Grant
- Patent Title: RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
-
Application No.: US15671220Application Date: 2017-08-08
-
Publication No.: US10246714B2Publication Date: 2019-04-02
- Inventor: Duncan Brown , James J. Cunningham , Marian Gindy , Victoria Pickering , Matthew G. Stanton , Steven M. Stirdivant , Walter R. Strapps
- Applicant: Sirna Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Sirna Therapeutics, Inc.
- Current Assignee: Sirna Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Deborah L. Nagle
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; C07H21/02 ; C07H21/04 ; C12N15/113
Abstract:
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
Public/Granted literature
Information query
